Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.

Journal Article (Review)

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy or alone in women with primary and recurrent ovarian cancer. Antiangiogenic agents include monoclonal antibodies, tyrosine-kinase inhibitors, and peptibodies. Many of these agents, including bevacizumab, pazopanib, nintedanib, cediranib, and trebananib, have been evaluated in randomized Phase III clinical trials, and all have demonstrated a progression-free survival (PFS) benefit. Specifically, maintenance pazopanib was shown to improve PFS in women with newly diagnosed EOC. Pazopanib, an oral TKI, inhibits several kinase receptors, including those for vascular endothelial growth factor (-1,-2,-3), platelet-derived growth factor (-α and -β), and fibroblast growth factor. It also targets stem cell-factor receptor (c-kit), interleukin 2-inducible T-cell kinase, lymphocyte-specific protein tyrosine kinase, and colony-stimulating factor 1 receptor. Pazopanib has been investigated in several Phase II and III clinical trials, with results indicating a potential role in the management of EOC. This article provides an overview of pazopanib in the treatment of EOC.

Full Text

Duke Authors

Cited Authors

  • Davidson, BA; Secord, AA

Published Date

  • January 2014

Published In

Volume / Issue

  • 6 /

Start / End Page

  • 289 - 300

PubMed ID

  • 24648773

Electronic International Standard Serial Number (EISSN)

  • 1179-1411

International Standard Serial Number (ISSN)

  • 1179-1411

Digital Object Identifier (DOI)

  • 10.2147/ijwh.s49781

Language

  • eng